A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (X-PLORE)
A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis (X-PLORE)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Brussel, Belgium
-
Gent, Belgium
-
Liege, Belgium
-
-
-
-
-
Quebec, Canada
-
-
Alberta
-
Edmonton, Alberta, Canada
-
-
British Columbia
-
Vancouver, British Columbia, Canada
-
-
New Brunswick
-
Moncton, New Brunswick, Canada
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada
-
-
Ontario
-
Hamilton, Ontario, Canada
-
London, Ontario, Canada
-
Oakville, Ontario, Canada
-
Toronto, Ontario, Canada
-
Waterloo, Ontario, Canada
-
-
Quebec
-
Montreal, Quebec, Canada
-
-
-
-
-
Hamburg, Germany
-
Mahlow, Germany
-
Munster, Germany
-
Schwerin, Germany
-
-
-
-
-
Gdansk, Poland
-
Konskie N/A, Poland
-
Lodz, Poland
-
Wroclaw, Poland
-
-
-
-
Alabama
-
Birmingham, Alabama, United States
-
-
California
-
Bakersfield, California, United States
-
Los Angeles, California, United States
-
Santa Monica, California, United States
-
-
Florida
-
Ocala, Florida, United States
-
-
Georgia
-
Alpharetta, Georgia, United States
-
-
Illinois
-
Arlington Heights, Illinois, United States
-
Skokie, Illinois, United States
-
-
Indiana
-
Indianapolis, Indiana, United States
-
-
Kentucky
-
Louisville, Kentucky, United States
-
-
Massachusetts
-
Andover, Massachusetts, United States
-
Boston, Massachusetts, United States
-
-
Missouri
-
Saint Louis, Missouri, United States
-
-
New Mexico
-
Albuquerque, New Mexico, United States
-
-
New York
-
New York, New York, United States
-
-
Oregon
-
Portland, Oregon, United States
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States
-
-
Texas
-
Houston, Texas, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of plaque-type psoriasis with or without psoriatic arthritis for at least 6 months prior to first administration of any study agent
- Must be a candidate for phototherapy or systemic treatment for psoriasis (either new to treatment or having had previous treatment)
- Must be considered, in the opinion of the investigator, suitable candidates for adalimumab therapy
- If a woman, she must be postmenopausal, or if premenopausal, she must be either surgically sterile, practicing a highly effective method of birth control, or not heterosexually active during the study and for 5 months after receiving the last dose of study drug
- If a man, he must agree to use a double-barrier method of birth control (or must have been surgically sterilized) and to not donate sperm during the study and for 5 months after receiving the last dose of study drug.
Exclusion Criteria:
- History of or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease
- Has a contra-indication to anti-TNF therapy
- Has a history of chronic or recurrent infectious disease
- Has a nonplaque form of psoriasis or has drug-induced psoriasis
- Has been previously treated with adalimumab
- Has received any therapeutic agent directly targeted to IL-12, IL-17, or IL-23, (including but not limited to ustekinumab, briakinumab [ABT-874], AIN457, and SCH900222) within 6 months of the first administration of study agent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: CNTO 1959 (5 mg)
CNTO 1959 5 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
|
Subcutaneous (SC) injections
|
|
Experimental: CNTO 1959 (15 mg)
CNTO 1959 15 mg at weeks 0, 8, and 16, then every 8 weeks through Week 40
|
SC injections
|
|
Experimental: CNTO 1959 (50 mg)
CNTO 1959 50 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
|
SC injections
|
|
Experimental: CNTO 1959 (100 mg)
CNTO 1959 100 mg at weeks 0, 8, and 16, then every 8 weeks through Week 40
|
SC injections
|
|
Experimental: CNTO 1959 (200 mg)
CNTO 1959 200 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
|
SC injections
|
|
Active Comparator: Adalimumab (approved psoriasis dosing)
Adalimumab 80 mg at week 0 followed by 40 mg at week 1 and every second week through Week 39 (i.e., Weeks 3, 5, 7, etc.)
|
SC injections
|
|
Placebo Comparator: Placebo to CNTO 1959 (100 mg)
Placebo at weeks 0, 4, and 8; then crossover to CNTO 1959 100 mg at Week 16, then every 8 weeks through Week 40
|
SC injections
SC injections
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 16
Time Frame: Week 16
|
PGA of psoriasis is used to determine the participant's psoriasis lesions overall at a given time point.
Lesions were graded as erythema [0 (no evidence of plaque) to 5 (dusky to deep red coloration)], induration [0 (no plaque evaluation) to 5 (marked plaque evaluation)] and scaling [0 (no evidence of scaling) to 5 (severe; very thick tenacious scaling)].
The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0= cleared; 1= minimal; 2= mild; 3= moderate; 4= marked and 5= severe).
|
Week 16
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16
Time Frame: Week 16
|
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy.
In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities.
Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72.
PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline.
|
Week 16
|
|
Difference in Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) in CNTO1959 Groups Compared With Adalimumab Group at Week 16
Time Frame: Week 16
|
PGA of psoriasis is used to determine the participant's psoriasis lesions overall at a given time point.
Lesions were graded as erythema [0 (no evidence of plaque) to 5 (dusky to deep red coloration)], induration [0 (no plaque evaluation) to 5 (marked plaque evaluation)] and scaling [0 (no evidence of scaling) to 5 (severe; very thick tenacious scaling)].
The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0= cleared; 1= minimal; 2= mild; 3= moderate; 4= marked and 5= severe).
|
Week 16
|
|
Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 40
Time Frame: Week 40
|
PGA of psoriasis is used to determine the participant's psoriasis lesions overall at a given time point.
Lesions were graded as erythema [0 (no evidence of plaque) to 5 (dusky to deep red coloration)], induration [0 (no plaque evaluation) to 5 (marked plaque evaluation)] and scaling [0 (no evidence of scaling) to 5 (severe; very thick tenacious scaling)].
The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0= cleared; 1= minimal; 2= mild; 3= moderate; 4= marked and 5= severe).
|
Week 40
|
|
Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16
Time Frame: Baseline and Week 16
|
The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life.
Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life.
The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life.
Higher scores indicate more impact on quality of life of participants.
|
Baseline and Week 16
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CR100673
- CNTO1959PSO2001 (Other Identifier: Janssen Inc.)
- 2011-001066-17 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.